Michael S. Saag

Active 1988–2024

Also published as
Michael S Saag
194
Papers
48,208
Citations
111
h-index
192
i10-index

Citations

Citations per year for Michael S. Saag1984: 1 citations1987: 1 citations1988: 11 citations1989: 36 citations1990: 43 citations1991: 44 citations1992: 40 citations1993: 55 citations1994: 72 citations1995: 135 citations1996: 210 citations1997: 242 citations1998: 262 citations1999: 230 citations2000: 267 citations2001: 233 citations2002: 223 citations2003: 271 citations2004: 308 citations2005: 256 citations2006: 264 citations2007: 280 citations2008: 373 citations2009: 384 citations2010: 479 citations2011: 412 citations2012: 387 citations2013: 414 citations2014: 274 citations2015: 300 citations2016: 315 citations2017: 201 citations2018: 250 citations2019: 964 citations2020: 852 citations2021: 677 citations2022: 461 citations2023: 327 citations2024: 578 citations2025: 202 citations2026: 7 citations1985–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,754 citing papers, 37.8% of this breakdownUnited Kingdom: 1,221 citing papers, 8% of this breakdownFrance: 683 citing papers, 4.5% of this breakdownCanada: 619 citing papers, 4.1% of this breakdownGermany: 527 citing papers, 3.5% of this breakdownSouth Africa: 475 citing papers, 3.1% of this breakdownSpain: 451 citing papers, 3% of this breakdownItaly: 434 citing papers, 2.8% of this breakdownSwitzerland: 413 citing papers, 2.7% of this breakdownNetherlands: 410 citing papers, 2.7% of this breakdownChina: 370 citing papers, 2.4% of this breakdownAustralia: 367 citing papers, 2.4% of this breakdown
0%37.8%Other 23%

Fields

  • Medicine57%
  • Immunology and Microbiology34.6%
  • Biochemistry, Genetics and Molecular Biology3.6%
  • Health Professions0.8%
  • Agricultural and Biological Sciences0.6%
  • Mathematics0.5%
  • Other2.9%

Topics

  • HIV Research and Treatment17.6%
  • HIV/AIDS Research and Interventions12.1%
  • HIV/AIDS drug development and treatment11.9%
  • HIV-related health complications and treatments6.9%
  • Immune Cell Function and Interaction4%
  • Hepatitis C virus research1.7%
  • Other45.8%

Coauthors

All papers

Open in search
  1. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

    Authors: , , , , , , , , , , , , , , , , , - JAMA 2022 cited by 551

  2. Antibody neutralization and escape by HIV-1

    Authors: , , , , , , , , , , , , , , - Nature 2003 cited by 2,460

  3. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Natasha T. Wood, Cathal Seoighe, Alan S. Perelson, Tanmoy Bhattacharya, Bette Korber, Beatrice H. Hahn, George M. Shaw - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 1,937

  4. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

    Authors: , , , , , , , , , , , , , , - JAMA 2016 cited by 656

  5. Updated Treatment Recommendation on Use of Cabotegravir and Rilpivirine for People With HIV From the IAS-USA Guidelines Panel

    Authors: , , , - JAMA 2024 cited by 51

  6. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

    Authors: , , , , , , , , , , , , , , , - JAMA 2020 cited by 467

  7. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy

    Authors: , , , , , , , , , - Antimicrobial Agents and Chemotherapy 2002 cited by 1,594

  8. HIV post-treatment controllers have distinct immunological and virological features

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2023 cited by 65

  9. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

    Authors: , , , , , , , , , , , , , - The Lancet 2014 cited by 501

  10. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel

    Authors: , , , , , , , , , , , , , , , , , , - JAMA 2024 cited by 202

  11. Viral dynamics in human immunodeficiency virus type 1 infection

    Authors: , , , , , , , , , , , - Nature 1995 cited by 3,294

  12. Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel R. Drozd, David A. Fiellin, David W. Haas, Gregory D. Kirk, James H. Willig, Jason Globerman, John T. Brooks, Joseph J. Eron, Joan Montaner, Karyn Gabler, Kathryn Anastos, Kenneth H. Mayer, Lisa P. Jacobson, Madison Kopansky-Giles, Marina B. Klein, Megan Turner, Michael J. Mugavero, Michael S. Saag, P. Richard Harrigan, Robert Dubrow, Robert F. Hunter-Mellado, Robert S. Hogg, Ronald J. Bosch, Rosemary G. McKaig, Sally Bebawy, Sean B. Rourke, Sonia Napravnik, Stephen Boswell, Timothy R. Sterling - Clinical Infectious Diseases 2017 cited by 180

  13. Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2017 cited by 154

  14. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor–Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2020 cited by 102

  15. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , George M. Shaw - The Journal of Experimental Medicine 2009 cited by 787

  16. Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2014 cited by 152

  17. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , George M. Shaw, Persephone Borrow, Katharine J. Bar, Beatrice H. Hahn - Science Translational Medicine 2021 cited by 83

  18. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2015 cited by 598

  19. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

    Authors: , , , , , , , , , , , , , , , , - JAMA 2018 cited by 559

  20. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

    Authors: , , , , , , , , , , , , , , - Nature Medicine 1998 cited by 994

  21. Invasive Cervical Cancer Risk Among HIV-Infected Women

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - JAIDS Journal of Acquired Immune Deficiency Syndromes 2012 cited by 231

  22. Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Julia Zhu, Kate Salters, Karyn Gabler, Kate Buchacz, John T. Brooks, Kelly A. Gebo, Richard D. Moore, Richard D. Moore, John T. Carey, Benigno Rodríguez, Michael A. Horberg, Michael J. Silverberg, Jennifer E. Thorne, Charles S. Rabkin, Lisa P. Jacobson, Gypsyamber DʼSouza, Marina B. Klein, Sean B. Rourke, Anita Rachlis, Jason Globerman, Madison Kopansky-Giles, Robert F. Hunter-Mellado, Ángel M. Mayor, M. John Gill, Steven G. Deeks, Jeffrey N. Martin, Pragna Patel, John T. Brooks, Michael S. Saag, Michael J. Mugavero, James H. Willig, Joseph J. Eron, Sonia Napravnik, Mari M. Kitahata, Heidi M. Crane, Daniel R. Drozd, Timothy R. Sterling, David W. Haas, Peter F. Rebeiro, Megan Turner, Sally Bebawy, Ben Rogers, Amy C. Justice, Robert Dubrow, David A. Fiellin, Stephen J. Gange, Kathryn Anastos, Richard D. Moore, Michael S. Saag, Stephen J. Gange, Mari M. Kitahata, Keri N. Althoff, Rosemary G. McKaig, Aimee M. Freeman, Richard D. Moore, Aimee M. Freeman, Carol Lent, Mari M. Kitahata, Stephen E. Van Rompaey, Heidi M. Crane, Daniel R. Drozd, Justin McReynolds, Justin McReynolds, William B. Lober, Stephen J. Gange, Keri N. Althoff, Alison G. Abraham, Bryan Lau, Jinbing Zhang, Jerry Jing and 6 more - Clinical Infectious Diseases 2017 cited by 89

  23. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

    Authors: , , , , , , , , , - AIDS 2015 cited by 87

  24. Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - International Journal of Epidemiology 2007 cited by 212